Together, these findings define an immunometabolic axis-AMPK/mTOR-arginine-TCA cycle coupling-that dictates microglial fate after stroke, and suggests VK as a therapeutic agent capable of concurrently targeting neuroinflammation, mitochondrial dysfunction, and metabolic imbalance. Here, MTOR is linked to stroke disorder.